Jul 02
LONDON/BOSTON (Reuters) – Johnson & Johnson has agreed to pay $1 billion for an 18.4 percent stake in Irish drugmaker Elan Corp, and will acquire most of the rights to Elan’s portfolio of experimental drugs to treat Alzheimer’s disease.



Leave a Reply
You must be logged in to post a comment.